5(10.0-21.9) mmHg] of the preterm infants were not significantly different compared to the SII [88.0 (74.6-110.0) mmHg] and SIII [13.5 (9.2-15.9) mmHg] of term infants (p=0.625 and p=0.144 respectively). SII was not significantly related to GA, duration of ventilation or FIO2. SIII was positively related to the duration of ventilation (r=0.729, p less then 0.001) and FIO2 (r=0.704, p less then 0.001). SIGNIFICANCE The volumetric capnography phase III slope was steeper in infants with higher ventilatory requirements, hence could potentially be used as an index of disease severity in ventilated newborns. © 2020 Institute of Physics and Engineering in Medicine.Cancer treatment has always been a big problem for people. With the application of photodynamic therapy, the problem has been alleviated. However, the problem of tumor hypoxia affecting photodynamic therapy has been waiting to be resolved. Therefore, we report here that a redox nanocarrier (called RN) is prepared by hollow mesoporous silica sphere (HMSNs) and a redox-responsive polymer ligand. The nanocarrier is loaded with metformin and catalase, and the polymer is linked to the photosensitizer chlorin e6 (Ce6). Metformin inhibits the mitochondrial respiration of cancer cells, reducing the activity of cancer cells and increasing the oxygen concentration required for photodynamic therapy. Not only the effect of photodynamic therapy is enhanced, but also the effect of chemotherapy is increased to achieve an effective synergistic treatment. These RNs exhibit not only low biotoxicity but also high biocompatibility in vitro experiments. In vitro Ce6 release studies have shown a higher release in the presence of glutathione (GSH). Confocal microscopy can further indicate that the nanoparticles are carried to the area around the nucleus of the cancer cells. In addition, treatment with a mouse tumor model demonstrated that RN has an effective therapeutic effect on tumors. © 2020 IOP Publishing Ltd.OBJECTIVE Translational studies on animals play a vital role in the advancement of transcranial magnetic stimulation (TMS) as clinical technique. Nonetheless the relevance of these procedures is frequently limited by the lack of TMS systems specifically designed for small animals capable of producing comparable stimulation conditions to those found in human TMS. In this work, we propose to take advantage of the versatility of recently introduced TMS coil design methods to produce optimal rodent-specific TMS stimulators. APPROACH A stream function inverse boundary element method (IBEM) has been used for producing three small sized mice-specific TMS coils of different geometries. They have been created for unilateral hemispheric stimulation of the rodent brain, and several constraints have been considered in the design process to satisfy essential performance requirements, such as minimum stored magnetic energy, minimum power dissipation, optimised maximum current density or minimization of the undesired electric field induced in non-target regions. In order to validate the presented strategy, three prototype coils have been built. The performance of each prototype has also been numerically investigated, where the electric field induced in a mouse model has been found by using an existing computational forward technique. Main results and conclusion Stream function IBEM represents an ideally suited approach for designing specific TMS coils for small animals, capable of fulfilling many essential functional and technical requirements. The prototypes produced in this work focally stimulate the right hemisphere of the mouse brain, and so they can be successfully used in lateralized TMS experiments. SIGNIFICANCE The design scheme proposed here can be used to produce efficient TMS stimulators for small animals, which can overcome some of the existing limitations found when producing more reliable translational experiments. © 2020 IOP Publishing Ltd.BACKGROUND Circular RNA is a type of non-coding RNA with great potential in regulating gene expression and associated with disease progression. However, the role of circular RNA in endometrial carcinoma (EC) remains largely unknown. RESULTS In this study, we found that circTNFRSF21 was highly expressed in EC cells and tumor tissues. In vitro and in vivo results showed that circTNFRSF21 was linked to increased EC cell growth and EC xenografts formation in nude mice. Mechanically, we showed that circTNFRSF21 acts as a sponge of miR-1227 in EC cells to rescue MAPK13/ATF2 signaling pathway activity. CONCLUSIONS Our studies suggested that in the EC, circTNFRSF21 promotes EC formation through downregulating miR-1227 expression and activating MAPK13/ATF2 signaling pathway. These findings provide strong evidence that circTNFRSF21-miR-1227-MAPK13/ATF2 axis is a promising target for EC treatment. METHODS qRT-PCR was used to detect circTNFRSF21expression in EC patients and EC cell lines. Cell growth, cell colony formation, cell apoptosis, cell cycle progression, and in vivo tumor formation assays were used to evaluate the roles of circTNFRSF21 in EC. Western blot, luciferase assay, RNA pull-down, siRNA knockdown, and CRISPR gene knock out assays were applied to study the mechanisms through which circTNFRSF21 regulates EC formation.Concurrent type 1 diabetes (T1D) and Addison's disease (AD) is a rare combination of diseases and, in approximately one third of these patients, it is also combined with an autoimmune thyroid disease. Recently, it was shown that patients with both T1D and AD have a higher risk of premature death compared to patients with T1D alone, the most common causes of death being due to diabetic complications and cardiovascular disease. These patients receiving replacement therapies with both insulin and glucocorticoids face an increased risk of hypo- and hyperglycemia, and diabetic ketoacidosis, and have a higher risk of adrenal crisis than patients with AD alone. Treatment challenges include the opposing effects of insulin and glucocorticoids on glucose homeostasis, and the need to balance and synchronize these two treatments. https://www.selleckchem.com/products/merbarone.html The rarity of this disease combination may explain the paucity of data on outcome and specific treatment strategies in this patient group. Based on this review, we suggest management strategies for their insulin and glucocorticoid replacement therapies and indicate future areas of research.